MedTrace Logo

Use of 1-MNA to Improve Exercise Tolerance and Fatigue in Patients After COVID-19

NCT04961476 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2021-07-21

No results posted yet for this study

Summary

Coronavirus disease 2019 (COVID-19) is a serious respiratory disease that results from infection with a newly discovered coronavirus (SARS-COV-2). Unfortunately, COVID-19 is not only a short-term infection but that patients (pts) recovering from SARS-COV2 infection complain of persisting symptoms including: fatigue, diffuse myalgia and weakness, which may lead to chronic fatigue syndrome. There is currently no evidence that nutritional supplements and/or physical exercise can assist in the recovery of pts with chronic fatigue syndrome. 1-Methylnicotinamide (1-MNA) is an endogenic substance that is produced in the liver when nicotinic acid is metabolized. 1-MNA demonstrates anti-inflammatory and anti-thrombotic properties. Therefore, we investigated whether 1-MNA supplements could improve exercise tolerance and decrease fatigue among patients recovering from SARS-COV-2.

Conditions

  • Covid19
  • Fatigue Syndrome, Chronic

Interventions

DIETARY_SUPPLEMENT

1-MNA

1-MNA supplementation

Sponsors & Collaborators

  • Michal Chudzik

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-08
Primary Completion
2021-03-05
Completion
2021-03-05

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04961476 on ClinicalTrials.gov